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While the science of human genomics is often focused on odds and
probability, most of us do not experience risk that way.
I am a carrier of a mutation in ABCC6, as is my husband. Rather than
experiencing the odds we would have children with the autosomal re-
cessive condition pseudoxanthoma elasticum (25% each pregnancy) as
an abstraction, our reality is having two of two children affected by
PXE: our experience is 100%. Twice.
PXE affects 1 in 50,000 people. Our kids are the numerators. In 1994,
when PXE was discovered in our then-very-young children, we felt not
only overwhelmed by the prospect of taking care of them and anxious
about the uncertainty of their futures, but isolated by the rare nature
of their condition. Genetics? We didn't want to talk about it then and
even if we did, we didn't have anyonewithwhomwe could talk about it.
Today? Not so much. We—and thousands of others in similar
circumstances—are bombardedwith information from sequencing cen-
ters, clinics, research studies, and direct-to-consumer sites. And, spam
fatigue notwithstanding, that's mostly to the good. Genetic disease is a
long-tail problem that can only be solved if crowdsourcing rises to the
occasion, that is, if families like mine and others contributing to and
discussed in this issue are not alone. Precision medicine, biomedical re-
search, and humanhealthwrit large all stand to beneﬁt if themasses get
involved. Indeed, I would argue that crowdsourcing is our only hope.
Here I describe ways in which this is already happening and a vision
for a future where it is standard practice.
2. Life on Mars
When our two children were diagnosed with PXE, it felt like we
landed on Mars and were being chased by the grim reaper. Fear ripped
through us, and no one was speaking words we could understand. This
was not just because we could not hear through our fear, but because
theworld of biomedical research and disease characterization has an in-
credibly esoteric and complex vocabulary. Even the sentence structures
were complicated — all passive voice and past tense. It was as though
the language—and by extension, our family—was not alive anymore.
As if it weren't terrifying enough to enter the stigma-ridden land of
The Diagnosed, we immediately discovered an astonishing fact: scien-
tists were not sharing. A few days after our kids' diagnoses, scientists
from Harvard came to draw blood from us to use in the search for the
causative gene. Two days after that, a separate group of scientists called
from theMt. Sinai Hospital in New York and asked for blood to work onhttp://dx.doi.org/10.1016/j.atg.2016.01.007
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the ﬁrst set for blood (and perhaps even collaborate), they expressed
amazement that we would ask such a thing! We were struck by how
the culture of science, particularly in biomedical research, had so col-
ored the researchers' perspectives that they found our request prepos-
terous. We felt both horriﬁed and hopelessly naive.
But this was only our ﬁrst foray into a world that left us surprised
over and over: a world alien and offensive to us in our need. It seemed
that publishing, getting tenure and getting promotedweremore impor-
tant than discovering what was causing PXE. We quickly got over our
expectations for a rapid treatment, let alone a cure. What we couldn't
get over were the lack of sharing and the intense competition among
scientists. Twenty years on we're still not over it.
In 1995 we built a biobank and stored the samples at a major med-
ical center. That was ﬁne until we wanted to share those precious sam-
ples beyond that particular university. After notifying the researchers
there thatwewere on ourway to the laboratory to take one of 20 stored
DNA aliquots per person, each of which we had deposited there our-
selves, we arrived to ﬁnd a lock on the freezer. Manymonths of arguing
ensued, and we ﬁnally called the vice president of the medical center.
He ordered the release of our samples. We informed the institution
that we would be moving the entire collection of hundreds of samples.
On the day we arrived to do that, we found the samples on a cart in the
hallway— thawed andwarm.We also saw thatweweremissing several
aliquots per person. We took our room-temperature samples across
town to freezer space we were renting. And then we took our anger
and disappointment and channeled them into changing the system.
A few years later, I spentmonths negotiating the opportunity to do a
natural history study of PXE at theNational Institutes of Health. I offered
to support the salary of a clinician researcher to do the study. Two glar-
ing disconnects emerged. The ﬁrst related to the study protocol. At this
point, I had collected 900 ﬁelds of data on 4000 people living with PXE
and knew something about its signs, symptoms and progression. But
the investigators were adamant that they would focus on measuring
phenotypic characteristics that had no correlation to PXE! They
discounted our experience and our copious data. Second, they refused
to let me be part of the study team. The “offer”was for me to sit in the
back of the room; someone even made a joke that I could carry one of
the researcher's briefcases. Their excuse for excluding me was that I
was not credentialed in biomedical research. Nevermind that I had the
equivalent of a PhD in PXE.
These experiences, and dozens of others, fueled a passion in me to
lead an organization that was focused on the very people who needthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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status andmore focused on improving the lives of patients and families.
I became interested in practical tools that could be applied to any dis-
ease or condition, that could help break down silos and enable sharing
despite systems and bureaucrats that were and are often obstacles to
the outcomes we seek.
Even more critical to me is trying to change the fundamental mis-
alignments embedded in health care and biomedical research. When
the President of the United States embraces the rhetoric of patient-
and participant-centric research, we can safely say it has reached new
heights. Indeed, it was music to my ears to sit in the East Wing in
early 2015 and hear Barack Obama say “… I′m proud we have so
many patients' rights advocates with us here today. They're not going
to be on the sidelines. It's not going to be an afterthought. They'll help
us design this initiative from the ground up, making sure that we
harness new technologies and opportunities in a responsible way”
(Anon., 2015).
As I write this nearly a year later, however, we have yet to see the
deep and essential fundamental shift. We are behaving as though we
believe that engagement and partnership have value, but we are still
not able to articulate that value, and we are not able to tell the truth
about the incentives that drive the biomedical research system. I sit in
discussions about “patient-centricity” and wonder why the way we
keep score remains rooted in tallies of publications and grant monies. I
understand that for systems to change to realize beneﬁcial health out-
comes requires a long timeline. But I do not apologize for my impa-
tience. Academia, regulators and even many in pharma seem to accept
the ideas that: 1) developing drugs requires a decade; and 2) patients
are passive data points in this process, i.e., they are to be collected, not
consulted.
3. Strange attractors
In most of my encounters with the biomedical research system and
its recent lust for big data – especially genotype and phenotype data – I′
ve found that that those who champion “engagement” often see it as a
useful euphemism for recruitment. At one level I understand this: I do
not advocate for engagement for engagement's sake. But neither do I re-
duce it to a top-down call for increased sample size at all costs.
I think that this new intense interest in engagement, participation,
and partnership is what chaos theorists David Ruelle and Floris Takens
would call a “strange attractor” (Ruelle and Takens, 1971). The deﬁni-
tion describes “basins of attraction within the system that lure the sys-
tem into a new pattern of activity.” Engagement and participation, I
hope and expect, will recenter the system and create authentic partner-
ships. Individuals, families and communities will take their rightful
place as co-designers of new ways of engaging with their health.
In this regard, I amall in on an experiment. Togetherwith Private Ac-
cess, an innovative technology company, Genetic Alliance has built the
Platform for Engaging Everyone Responsibly (PEER). It shifts the center
of attention away from institutions, researchers, and even advocacy or-
ganizations, and toward individuals. Using PEER, each individual makes
choices about data sharing, privacy, and access in a granular and dynam-
icway. It is ourﬁrmbelief (andwehave invited researchers to study this
hypothesis) that if people make these choices for themselves, they will
drive the market. They will aggregate themselves not in disease silos,
but in pathways, phenotypes and symptoms that they strongly feel
need attention and to which they are prepared to commit.
How does PEER work? In one example, we engaged with ﬁve sickle
cell advocacy organizations and were able to learn from individuals liv-
ing with sickle cell what mattered to them, and to deliver this informa-
tion, along with patients' associated socioeconomic data, to the Food
and Drug Administration for its Patient-Focused Drug Development
program. We therefore extended the reach of the FDA's program toindividuals who couldn't travel to metro DC to attend a hearing, or
whowere not able to post to the docket (the special web-based system
that the government uses to catalog public comments).
In another example that is ongoing, ten disease advocacy organiza-
tions areworking together in a boundary-freeway to use the health infor-
mation they collect across 15 diseases encompassing seemingly unrelated
common (e.g., hepatitis, breast cancer) and rare (e.g., dyskeratosis
congenita, Joubert syndrome) conditions. As a part of PCORnet, the na-
tional clinical research network being created by the Patient Centered
Outcomes Research Institute (PCORI), these organizations are working
to deﬁne research priorities and advance them together. This example is
just one of 20 Patient-Powered Research Networks (PPRN) in PCORI
that seek to run dozens of experiments on what constitutes true
participant-centric research, how to build a network that will shift the
current paradigm, and how to develop more robust strange attractors,
all while measuring their impact on the current research and services
system.
Plenty of obstacles and challenges to these sorts of approaches re-
main. Large-scale research on human beings is a young pursuit. And for-
mal governance of it is even younger. Most of the same incentives that
kept researchers from sharing samples and data in 1994 are still in
place. Andwhile patient- and participant-advocates are more frequent-
ly invited to discussions surrounding research initiatives, we are still
routinely marginalized: we have a seat at the table but rarely do we
get to have any meaningful say about what's on the menu or who
should be invited to the meal. I hear rhetoric calling for “bridging to
‘those’ people” and “inviting them in.” But to my ears those terms are
harsh and grating: they perpetuate an “us” and a “them.”We are all us
and we are all them.
4. Street cred
The “us and them” frame is more than a linguistic peeve. In recent
years, those of uswhohave been at this for awhile have found our legit-
imacy called into question. There are those, evenwithin the patient and
participant advocacy movements, who now routinely discount what
some of us do. Some claim that we are not ‘true patients’ because we
have peer-reviewed papers, conduct research, lead large organizations
and/or work to inﬂuence policy at multiple levels—we are “them.” In
ways that I ﬁnd both saddening and ironic, it seems that our very efforts
have somehow sowed distrust. We are suddenly written off as having
Stockholm syndrome or not truly representing patients.
More than any slight from a researcher ever could, hearing this from
fellow advocates hurts. I am still, ﬁrst and foremost, mother to my two
children who live with a genetic condition. I would much rather my
family not live life as a numerator, but I—like all families coping with
any of the thousands of serious health conditions, be they common or
rare—have no choice. All we can do is ﬁght.
Meanwhile, my daughter has succeeded me as the executive direc-
tor of PXE International. She has doubled the organizational budget
and doubled the number of affected individuals enrolled in two short
years. Hermission, likemine, remains unchanged: it is not to have a sci-
entiﬁc career or access to power, but to alleviate suffering—her own, her
brother's, and the thousands like them.
When we have done that for the larger community of numerators,
we will gladly shut off the lights and go home.
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